Stocks · News reference

Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $30

Aug 14, 2026, 5:10 PMBenzinga Newsdesk

Oppenheimer analyst Jeff Jones maintains MediWound (NASDAQ:MDWD) with a Outperform and lowers the price target from $32 to $30.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 1:43 PMBenzinga Insights
MediWound Q2 2026 Earnings Call: Complete Transcript
MediWound (NASDAQ:MDWD) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
MDWD
BenzingaAug 13, 2026, 11:02 AMBenzinga Newsdesk
MediWound Q2 EPS $(0.77) Misses $(0.76) Estimate, Sales $3.092M Beat $2.588M Estimate
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.76) by 1.32 percent. This is a 37.4 percent increase over losses of $(1.23) per share from the
MDWD
BenzingaAug 13, 2026, 11:00 AMBenzinga Newsdesk
MediWound Affirms FY2026 Sales Guidance of $24.000M-$26.000M vs $24.125M Est
MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000 million-$26.000 million vs $24.125 million estimate.
MDWD